Editas Medicine, Inc. (EDIT)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Gilmore O'Neill M.D.
|
President, CEO & Director | 1.07M | -- | 1964 |
|
Ms. Amy Parison
|
Senior VP & CFO | 555.52k | -- | 1986 |
|
Dr. Linda C. Burkly Ph.D.
|
Executive VP & Chief Scientific Officer | 734.97k | -- | 1957 |
|
Dr. Feng Zhang Ph.D.
|
Co-Founder & Scientific Advisory Board Member | -- | -- | -- |
|
Dr. George McDonald Church Ph.D.
|
Co-Founder & Scientific Advisory Board Member | -- | -- | 1954 |
|
Mr. Gregory Whitehead
|
Executive VP and Chief Technical & Quality Officer | -- | -- | -- |
|
Mr. Damien Grierson J.D.
|
Senior VP, General Counsel & Corporate Secretary | -- | -- | -- |
|
Mr. Tom Love
|
Vice President of People | -- | -- | -- |
|
Mr. Frank Panaccio
|
Senior VP & Chief Business Officer | -- | -- | -- |
|
Ms. Brieana Buckley
|
Senior Vice President of Development and Program Leadership | -- | -- | -- |
Editas Medicine, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 87
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
November 9, 2026 at 9:00 PM UTC
Editas Medicine, Inc. Earnings Date
